Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
FGEN Stock Forecast 2026-2027
$9.50
Current Price
$38.43M
Market Cap
Buy 0
Hold 1
Sell 0
Wall St Analyst Ratings
Distance to FGEN Price Targets
+352.6%
To High Target of $43.00
+352.6%
To Median Target of $43.00
+352.6%
To Low Target of $43.00
FGEN Price Momentum
0.0%
1 Week Change
-5.4%
1 Month Change
-36.5%
1 Year Change
+8.2%
Year-to-Date Change
-56.7%
From 52W High of $21.94
+95.9%
From 52W Low of $4.85
📊 TOP ANALYST CALLS
Did FGEN Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if FibroGen is one of their latest high-conviction picks.
Latest FGEN Stock Price Targets & Analyst Predictions
Based on our analysis of 2 Wall Street analysts, FGEN has a neutral consensus with a median price target of $43.00 (ranging from $43.00 to $43.00). The overall analyst rating is N/A (N/A/10). Currently trading at $9.50, the median forecast implies a 352.6% upside. This outlook is supported by 0 Buy, 1 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Matthew Keller at HC Wainwright & Co., projecting a 352.6% upside. Conversely, the most conservative target is provided by Matthew Keller at HC Wainwright & Co., suggesting a 352.6% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
FGEN Analyst Ratings
0
Buy
1
Hold
0
Sell
FGEN Price Target Range
Low
$43.00
Average
$43.00
High
$43.00
Current: $9.50
Latest FGEN Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for FGEN.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Sep 24, 2025 | HC Wainwright & Co. | Matthew Keller | Buy | Reiterates | $43.00 |
| Aug 7, 2025 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| May 13, 2025 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Mar 18, 2025 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Feb 20, 2025 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Aug 8, 2023 | B of A Securities | Underperform | Downgrade | $N/A | |
| Jun 27, 2023 | Raymond James | Market Perform | Downgrade | $N/A | |
| Jun 27, 2023 | Goldman Sachs | Sell | Maintains | $N/A | |
| Jun 26, 2023 | B of A Securities | Neutral | Downgrade | $N/A | |
| Jun 26, 2023 | William Blair | Market Perform | Downgrade | $N/A | |
| Jun 26, 2023 | Raymond James | Market Perform | Downgrade | $N/A | |
| Jun 26, 2023 | Stifel | Hold | Downgrade | $N/A | |
| Jun 2, 2023 | Stifel | Buy | Upgrade | $N/A | |
| Feb 28, 2023 | Cowen & Co. | Market Perform | Maintains | $N/A | |
| Feb 23, 2023 | Goldman Sachs | Sell | Maintains | $N/A | |
| Feb 21, 2023 | Goldman Sachs | Sell | Maintains | $N/A | |
| Jan 31, 2023 | William Blair | Outperform | Upgrade | $N/A | |
| Jan 26, 2023 | Raymond James | Outperform | Upgrade | $N/A | |
| Jan 5, 2023 | B of A Securities | Buy | Upgrade | $N/A | |
| Nov 8, 2022 | Goldman Sachs | Sell | Maintains | $N/A |
FibroGen, Inc (FGEN) Competitors
The following stocks are similar to FibroGen based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
FibroGen, Inc (FGEN) Financial Data
FibroGen, Inc has a market capitalization of $38.43M with a P/E ratio of -0.8x. The company generates $8.30M in trailing twelve-month revenue with a 2,598.9% profit margin.
Revenue growth is +774.8% quarter-over-quarter, while maintaining an operating margin of -499.1% and return on equity of +25.9%.
Valuation Metrics
Market Cap
$38.43M
Enterprise Value
$-24,709,730
P/E Ratio
-0.8x
PEG Ratio
-0.8x
Price/Sales
4.7x
Growth & Margins
Revenue Growth (YoY)
+774.8%
Gross Margin
+105.4%
Operating Margin
-499.1%
Net Margin
+2,598.9%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+307.0%
Current Ratio
3.7x
Debt/Equity
111.4x
ROE
+25.9%
ROA
-18.4%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
FibroGen, Inc (FGEN) Business Model
About FibroGen, Inc
What They Do
Develops therapeutics for serious medical needs.
Business Model
FibroGen, Inc. engages in the discovery, development, and commercialization of biopharmaceuticals, primarily focusing on treatments for conditions like anemia in chronic kidney disease. The company generates revenue through the sale of its therapeutics, which includes lead products like Roxadustat and others in its pipeline, as well as collaboration agreements with major pharmaceutical companies.
Additional Information
Founded in 1993 and based in San Francisco, California, FibroGen has products in various stages of clinical development and is focused on addressing unmet medical needs, which may provide significant growth opportunities in the biopharmaceutical market.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
225
CEO
Mr. Thane Wettig
Country
United States
IPO Year
2014
Website
www.fibrogen.comFibroGen, Inc (FGEN) Latest News & Analysis
Latest News
Quick Summary
FibroGen, Inc. will rebrand as Kyntra Bio, focusing on oncology and rare diseases. The stock will trade under the new symbol "KYNB" starting January 8, 2026.
Why It Matters
FibroGen's rebranding to Kyntra Bio and focus shift to oncology and rare diseases may signal a strategic pivot, potentially impacting future growth and investor sentiment.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
FibroGen, Inc. (FGEN) will hold its Q3 2025 earnings call on November 10, 2025, at 5:00 PM EST, featuring CEO Thane Wettig and CFO David DeLucia.
Why It Matters
FibroGen's Q3 2025 earnings call indicates upcoming insights into financial performance and strategic direction, impacting investor sentiment and stock valuation.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
FibroGen (FGEN) reported a quarterly loss of $1.61 per share, better than the Zacks estimate of a $4.01 loss and an improvement from a loss of $4.25 per share a year earlier.
Why It Matters
FibroGen's smaller-than-expected loss indicates improved financial health, potentially boosting investor confidence and impacting stock performance positively.
Source: Zacks Investment Research
Market Sentiment:
Negative
Quick Summary
FibroGen, Inc. (NASDAQ: FGEN) will release Q3 2025 financial results on November 10 after market close and hold a conference call at 5:00 PM ET to discuss performance.
Why It Matters
FibroGen's upcoming financial results and conference call may impact stock price and investor sentiment, providing insights into the company's performance and future prospects.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
FibroGen, Inc. (NASDAQ: FGEN) has launched a Phase 2 trial for FG-3246, an ADC targeting mCRPC, and will evaluate the companion PET imaging agent FG-3180's effectiveness in identifying lesions.
Why It Matters
FibroGen's Phase 2 trial for FG-3246 could lead to a groundbreaking treatment for mCRPC, potentially boosting the company's stock value and attracting investor interest in innovative cancer therapies.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
FibroGen, Inc. (NASDAQ: FGEN) will present at the H.C. Wainwright 27th Annual Global Investment Conference in New York from September 8-10, 2025.
Why It Matters
FibroGen's presentation at a major investment conference could attract investor interest, potentially impacting stock performance and market perception of the company's growth prospects.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About FGEN Stock
What is FibroGen, Inc's (FGEN) stock forecast for 2026?
Based on our analysis of 2 Wall Street analysts, FibroGen, Inc (FGEN) has a median price target of $43.00. The highest price target is $43.00 and the lowest is $43.00.
Is FGEN stock a good investment in 2026?
According to current analyst ratings, FGEN has 0 Buy ratings, 1 Hold ratings, and 0 Sell ratings. The stock is currently trading at $9.50. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for FGEN stock?
Wall Street analysts predict FGEN stock could reach $43.00 in the next 12 months. This represents a 352.6% increase from the current price of $9.50. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is FibroGen, Inc's business model?
FibroGen, Inc. engages in the discovery, development, and commercialization of biopharmaceuticals, primarily focusing on treatments for conditions like anemia in chronic kidney disease. The company generates revenue through the sale of its therapeutics, which includes lead products like Roxadustat and others in its pipeline, as well as collaboration agreements with major pharmaceutical companies.
What is the highest forecasted price for FGEN FibroGen, Inc?
The highest price target for FGEN is $43.00 from Matthew Keller at HC Wainwright & Co., which represents a 352.6% increase from the current price of $9.50.
What is the lowest forecasted price for FGEN FibroGen, Inc?
The lowest price target for FGEN is $43.00 from Matthew Keller at HC Wainwright & Co., which represents a 352.6% increase from the current price of $9.50.
What is the overall FGEN consensus from analysts for FibroGen, Inc?
The overall analyst consensus for FGEN is neutral. Out of 2 Wall Street analysts, 0 rate it as Buy, 1 as Hold, and 0 as Sell, with a median price target of $43.00.
How accurate are FGEN stock price projections?
Stock price projections, including those for FibroGen, Inc, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: January 15, 2026 9:55 AM UTC